Assessing Medicines for Use in the Geriatric Population

Area of Science:

• Pharmacology
• Geriatric Medicine
• Regulatory Science

Background:

• Aging significantly impacts drug pharmacokinetics, pharmacodynamics, and adverse effect susceptibility.
• Older adults, particularly those aged 85+, with comorbidities, or on polypharmacy, are often underrepresented in clinical trials.
• Current prescribing guidelines may lead to inappropriate prescriptions and increased risks for elderly populations.

Purpose of the Study:

• To outline the European Medicines Agency's (EMA) regulatory approach for assessing new medicinal products.
• To address the challenge of balancing data acquisition with patient safety in early drug development.
• To ensure adequate consideration of the older adult population in new drug evaluations.

Main Methods:

• Review of the European Medicines Agency's (EMA) regulatory framework for new drug assessment.
• Analysis of strategies to incorporate data on older populations into drug evaluation processes.
• Examination of approaches to identify and communicate knowledge and evidence gaps.

Main Results:

• The EMA employs a structured approach to evaluate new medicines, considering age-related physiological changes.
• Strategies are in place to address the underrepresentation of older adults in clinical trials.
• Emphasis is placed on transparency regarding evidence gaps for healthcare professionals and patients.

Conclusions:

• The EMA's regulatory process aims to ensure new medicines are assessed with due consideration for the older adult population.
• Clear communication of evidence gaps is crucial for informed prescribing and patient safety.
• Balancing regulatory requirements with the need to protect vulnerable patient groups is a key challenge.